About us
Who we are?
Receptor.AI is a TechBio company setting new standards in drug discovery through its multiplatform AI ecosystem.
We build technologies that solve what conventional methods can’t — uncovering hidden binding sites, designing highly selective, orally available small molecules and peptides, and addressing “undruggable” targets with precision and evidence.
Behind every model stands a team of scientists, engineers, and industry veterans who have spent years advancing real drug discovery programs. Their experience shapes how we design, validate, and measure everything we create.
Our goal is clear: to make the creation of new therapeutics faster, more rational, and transparently grounded in science, so breakthroughs become not a matter of chance, but of design.
Dr. Alan Nafiev
Chief Executive Officer,
Founder
PhD in Data Science. Leads the development of decision-driven AI systems for drug discovery, focusing on adaptive screening cascade orchestration and multiparameter optimization under biological assay constraints. Brings 15+ years of experience at the intersection of data science, life sciences, and AI platforms, translating computational methods into deployable discovery workflows and program-level decision support.
Dr. Sergii Starosyla
Chief Technical Officer,
Co-founder
PhD in Molecular Biology with 15+ years of experience in drug discovery and scientific software development. Builds production-grade scientific software and optimization infrastructure for molecular discovery and ML-based prioritization engines. Combines medicinal chemistry practice with scalable platform engineering to enable auditable, multi-fidelity screening workflows and robust decision logging across discovery campaigns.
Dr. Semen Yesylevskyy
Chief Scientific Officer,
Co-founder
PhD in Biophysics. 25+ years of expertise in molecular modeling and membrane biophysics, with deep focus on simulating realistic membranes, membrane protein, drug–membrane interactions and permeability mechanisms. Develops physics-informed methods for assessing membrane permeability of challenging molecules (including conformationally flexibly chameleonic macrocycles) that aim to support complex drug discovery workflows.
Dr. Askar Kuchumov
Head of Business Development
Ph.D. in Biochemistry and Molecular Biology with 15+ years of experience in biotech business development and venture capital. Co-founder of several oncology startups, successfully advancing two first-in-class programs from discovery to Phase II clinical trials. Co-author in 20+ peer-reviewed publications, and 2 patent applications.
Dr. Volodymyr Bdzhola
Head of Medicinal Chemistry
PhD in Chemistry with 25 years of research experience, a pivotal member of the Institute of Molecular Biology and Genetics of the National Academy of Sciences of Ukraine, currently serving as a Senior Research Scientist and Deputy Head of the Department of Medicinal Chemistry. Contributed to over 65 scientific publications, showcasing his extensive research in the field.
Dr. Andrew Golub
Head of Computational Chemistry
PhD in Molecular Biology with 20+ years in Industry and Academia, specializing in CADD, computational chemistry, and cheminformatics. Expert in protein structure analysis, drug mechanisms, and therapeutic design. Co-author of multiple scientific papers and patents.
Dr. Yaroslav Bilokin
Head of Chemistry
PhD in Chemistry with 30+ years in medicinal and synthetic organic chemistry. Executive Director at OTAVA Ltd. with numerous patents and peer-reviewed publications. Combines expertise and leadership to tackle complex chemistry problems and lead innovative projects.
Dr. Jon Come
Medicinal Chemistry
PhD in Organic Chemistry from MIT with 20+ years of experience in medicinal chemistry, lead generation, and small-molecule drug discovery across oncology, infectious disease, immune disorders, and rare diseases. He has held senior scientific roles across the biotechnology industry, contributing to the design and advancement of drug discovery programs.
Dr. Daniele Andreotti
Medicinal Chemistry
Drug discovery expert with 30+ years of experience in medicinal chemistry, project leadership, and preclinical drug discovery. He has contributed to the advancement of more than 15 preclinical candidates and led integrated programs from hit identification to candidate selection across CNS, anti-infective, and metabolic disease areas.
Dr. Morten P. Meldal
Scientific Advisor
Nobel Laureate in Chemistry 2022 for inventing the click chemistry reaction (CuAAC). PhD in chemical engineering with 40+ years of experience in peptide synthesis and combinatorial chemistry. Professor at the University of Copenhagen, author of over 300 scientific publications and 21 patents in synthetic and molecular chemistry.
.avif)
Dr. Rajiah Aldrin Denny
Chief Scientific Advisor
Ph.D in Computational Sciences with 25+ years experience in the industry, including Pfizer and Biogen. Delivered 8 new chemical entities (NCEs) to the clinic/FIH assessment. Worked on over 60+ lead identification & optimization projects covering small molecules, peptides, ADCs, and degraders in a variety of indications.
Dr. Tomi K. Sawyer
Scientific Advisor: Peptide Drug Discovery
Leading expert in peptide drug discovery with 40 years of experience in pharma and biotech. He contributed to the development of FDA-approved drugs like Scenesse® and Iclusig®. Sawyer has held senior positions at Merck, Pfizer, and Ariad Pharmaceuticals. He is also recognized for over 600 scientific publications and patents in drug discovery.
Dr. Andrew Golub
Scientific Advisor: CADD
PhD in Molecular Biology with 20+ years in Industry and Academia, specializing in CADD, computational chemistry, and cheminformatics. Expert in protein structure analysis, drug mechanisms, and therapeutic design. Co-author of multiple scientific papers and patents.
Dr. Elisabetta Chiarparin
Scientific Advisor: Drug Discovery
Ph.D. in Chemistry with 20+ years of experience leading drug discovery in oncology, neuroscience, and immunology at Merck, GSK, Astex, and AstraZeneca. An expert in structure-based and AI-guided design, she has advanced multiple preclinical and clinical candidates, including molecular glues and PPI modulators, targeting challenging proteins and novel binding sites.
Prof. Kevin Burgess
Scientific Advisor: PPI Modulators
Renowned Rachal Professor of Chemistry at Texas A&M, who has made significant contributions to the fields of medicinal and combinatorial chemistry. He applies his expertise in peptido-mimetics, hybrid-peptides and PPI targeting.
Dr. Margot Ernst
Scientific Advisor: Receptor Pharmacology
PhD in Chemistry and Associate Professor at the Medical University of Vienna with 20+ years of experience in receptor pharmacology, ion channel biology, membrane protein modeling, and structure-guided drug discovery. Her work has contributed to structural insights into ligand-gated receptors and the discovery of novel receptor binding sites.
Jeff O’Meara, MSc
Scientific Advisor: Drug Discovery
With over 25 years in drug discovery, Jeff has led programs across antivirals, oncology, and CNS. His expertise includes medicinal chemistry, targeted degradation, and AI-integrated discovery strategies, with a strong track record of advancing assets into clinical development. He has authored 50+ scientific papers and patents.
Prof. Christophe Ramseyer
Scientific Advisor: Membrane Biophysics
PhD, Professor of Physics with 20+ years of experience in quantum chemistry and computational drug design. An expert in simulating interactions of theragnostic nanoparticles with the cell membrane.
Prof. Mikhail Bogdanov
Scientific Advisor: Membrane Molecular Biology
PhD, Professor of Biochemistry and Molecular Biology at University of Texas Medical School with 30+ years of experience in experimental studies of lipid membranes and membrane proteins. An expert in design and assessment of membrane targeting compounds.
Roman Stratiichuk
AI Drug Discovery
Project Manager
Taras Voitsitskyi
AI Technical Lead
Valerii Vasylevskyi
Head of Operations
.avif)
Myroslav Uiazdovskyi
Business Development Executive
Pavlo Henitsoi
Drug Discovery
Platform Developer
Ivan Khorpachov
AI Drug Discovery
Cloud Engineer
Vladyslav Husak
Platform Manager
Ihor Koleiev
Scientist
Medicinal Chemist
Roman Klymovych
Frontend Developer
Tigran Tsaturyan
Drug Discovery Project Manager
Ivanna-Mariia Klymkovych
Drug Discovery Operations
Sasha Korogodski
Drug Discovery Project Manager
Daniil Todoryshyn
Product Marketing
Manager
Aleksandr Al-Sayed
Platform Operations
Manager
Martin Indarte
Senior Computational Chemist
Anton Dasiuk
Back-end Developer
Mykola Melnychenko
ML Researcher
Roman Kyrylenko
ML Researcher
Oleksandr Kot
ML Researcher
Sofiia Shvets
ML Engineer
Hlib Kholodulkin
Business Administration Manager
Kateryna Yosypenko
Contract Administrator
Yevgen Khikhlo
Sales Administrator
Illia Savchenko
ML Researcher
Tetiana Skakun
Marketing Manager
Daryna Kyrylova
Business Development
Representative
.png)
Anastasiia Boshtova
Business Development
Representative
Olha Nadiievets
HR Manager
Latest Updates
Our Locations
UK Headquarters
United Kingdom,
20-22 Wenlock Road,
London N1 7GU
R&D facility
Experimentelle Fabrik,
Germany, Sandtorstraße 23,
39106 Magdeburg
US Headquarters
Cambridge, MA 02140
